• Separate subgroup analysis demonstrates long-term efficacy of Ofev® in slowing disease progression is maintained for up to 96 weeks in IPF patients who require dose adjustments to manage adverse events
  • An additional pooled analysis where the majority of IPF patients (90%) had high cardiovascular (CV) risk showed the incidence of major adverse CV events was low and comparable between Ofev® and placebo-treated patients

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the presentation of new analyses on the use of Ofev® (nintedanib) in treating idiopathic pulmonary fibrosis (IPF) at the 2017 American Thoracic Society (ATS) conference. Abstracts presented at the conference support the established efficacy and safety data for Ofev and offer further insights into its effect on lung function in IPF patients.

Pooled data from the two Phase III INPULSIS® trials showed that Ofev-treated patients were twice as likely as those given placebo to experience an improvement or no decline in lung function, as measured by forced vital capacity (FVC), at week 52 (36.8%, Ofev vs. 18.0%, placebo). A subgroup analysis of the open-label INPULSIS®-ON study demonstrated a similar annual rate of FVC decline over 96 weeks among Ofev-treated patients, regardless of the dosage they received based on individual tolerability (150 mg twice daily, 100 mg twice daily, or both doses).

Additionally, a pooled analysis from the TOMORROW, and INPULSIS® trials assessed the incidence rates for major adverse cardiovascular events (MACE) among patients treated with Ofev and placebo. Most patients included in this analysis (90%) had a high cardiovascular (CV) risk at baseline, including a history of fatty-plaque build-up in the arteries (called atherosclerosis) and/or at least one CV risk factor such as high blood pressure, diabetes or elevated blood cholesterol levels. Overall, the incidence of MACE was similar between the treatment groups both in patients with a high CV risk (3.5%, Ofev vs. 3.3%, placebo) and low CV risk (4.5%, Ofev vs. 5.3%, placebo) at baseline.

“IPF is a progressive disease that requires ongoing treatment. So, it is important to assess the long-term efficacy and safety of IPF treatments like Ofev to ensure we are maintaining lung function and reducing disease progression while not exacerbating co-existing conditions,” said Imre Noth, M.D., professor of medicine and director of the Interstitial Lung Disease Program at the University of Chicago. “These new data help to further strengthen the science supporting the efficacy and safety of Ofev for up to 96 weeks of treatment, and offer physicians additional evidence to support their treatment decisions.”

New Insights about IPF Patients
A separate analysis presented at ATS examined data from the IPF-PRO patient registry at 18 pulmonary care sites to identify the clinical characteristics of IPF patients who have advanced lung function impairment. Most clinical studies have included IPF patients with mild to moderate lung function impairment, and investigators wanted to understand how patients with more advanced disease differed. Patients with advanced IPF at baseline had greater physical impairment versus patients with mild to moderate disease, including lower six-minute walk distance (320 feet vs. 397 feet). The more advanced IPF patients also had an increased prevalence of hypoxemia (low blood oxygen), both at rest (36.6% vs. 7.4%) and while active (62.4% vs. 20.2%), requiring more supplemental oxygen, as well as a history of pulmonary arterial hypertension, or high blood pressure in the lungs (14.0% vs. 6.4%). In addition, health-related quality of life (HRQL) scores were significantly worse in those with advanced lung function impairment.

“At Boehringer Ingelheim, we are committed to IPF and broader ILD research and advancements to better understand these devastating diseases,” said Thomas Leonard, Ph.D., executive director, Clinical Development and Medical Affairs, Specialty Care, Boehringer Ingelheim Pharmaceuticals, Inc. “Through ongoing research, we are able to provide the IPF community with the information they need to make informed treatment decisions.”

Ongoing research is being conducted for the treatment of Ofev in patients with IPF and other interstitial lung diseases. Nintedanib is also being investigated for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD), as well as progressive fibrosing interstitial lung disease (PF-ILD). Additionally, the first Phase IV trial(link is external) following the approval of Ofev for the treatment of IPF is completed and will add evidence to the safety and tolerability of nintedanib in combination with pirfenidone. Results from the 12-week, randomized INJOURNEY trial will be presented at an upcoming international medical congress.

The corresponding abstracts can be found within the online program, here:
https://cms.psav.com/ats2017/confcal(link is external)

About idiopathic pulmonary fibrosis (IPF)
IPF is a rare and serious lung disease that causes permanent scarring of the lungs. It affects as many as 132,000 Americans, typically men over the age of 65. Early diagnosis and proper care are critical to helping people treat their condition.

About the INPULSIS® trials
INPULSIS®-1 and -2 are two global Phase III trials which evaluated the efficacy and safety of nintedanib in the treatment of idiopathic pulmonary fibrosis (IPF). The INPULSIS® trials were identical in design, e.g., with matching dosing, inclusion criteria and endpoints. INPULSIS® recruited a range of patient types – similar to those seen in clinical practice including patients with early disease (FVC > 90% pred), no honeycombing on HRCT and/or concomitant emphysema. Patients who completed the 52-week treatment period and a 4-week follow-up period in the INPULSIS® trials were offered open-label treatment with Ofev® as part of an extension trial to assess the long-term safety and tolerability of Ofev. The INPULSIS®-ON (Clinicaltrial.gov trial identifier: NCT01619085) trial included 734 patients and is currently ongoing.

About Ofev® (nintedanib)
The U.S. Food and Drug Administration (FDA) approved Ofev for the treatment of idiopathic pulmonary fibrosis (IPF) on October 15, 2014. Ofev is one of the first FDA-approved drug treatments for IPF and the only kinase inhibitor approved to treat this disease.

The approval was based on findings from a robust clinical trial program involving more than 1,200 patients with IPF worldwide, and included the Phase II TOMORROW trial and the Phase III INPULSIS® trials (INPULSIS®-1 and INPULSIS®-2. All these studies were randomized, double-blind, placebo-controlled trials comparing Ofev 150 mg twice daily to placebo for 52 weeks. Both INPULSIS® trials were identically designed while the TOMORROW study design was similar.

What is Ofev?
Ofev is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF). It is not known if Ofev is safe and effective in children.

186 thoughts on “IPF Patients Treated with Ofev® VS Placebo Were Twice as Likely to Have Improved or Stable Lung Function”

  1. Pingback: sarahtkaye
  2. Pingback: umarked
  3. Pingback: stonessmile
  4. Pingback: eddmtogo
  5. Pingback: sellergyllc
  6. Pingback: valregal
  7. Pingback: sedfab
  8. Pingback: flatlandip
  9. Pingback: bitestats
  10. Pingback: galsing
  11. Pingback: ppmataro
  12. Pingback: judycarlton
  13. Pingback: lisupplyco
  14. Pingback: boekstuk
  15. Pingback: kamelefon
  16. Pingback: tatesburger
  17. Pingback: thocbdc
  18. Pingback: kabatecnico
  19. Pingback: vikingak
  20. Pingback: therawplate
  21. Pingback: wanakahomes
  22. Pingback: spacesmacks
  23. Pingback: refreshbr
  24. Pingback: grasslandip
  25. Pingback: nolteknows
  26. Pingback: enewsreporter
  27. Pingback: monctondjs
  28. Pingback: encweddings
  29. Pingback: radiohaatuf
  30. Pingback: seacrs
  31. Pingback: sarahlynnw
  32. Pingback: cavalangue
  33. Pingback: chinookpier
  34. Pingback: leekoil
  35. Pingback: colespeirs
  36. Pingback: gotapool
  37. Pingback: capitolv
  38. Pingback: fugowski
  39. Pingback: envirofilt
  40. Pingback: lktvchannel
  41. Pingback: fredmarvin
  42. Pingback: vtlasers
  43. Pingback: billsodds
  44. Pingback: midiparts
  45. Pingback: teamvie
  46. Pingback: cheerforace
  47. Pingback: lizordonez
  48. Pingback: motobc
  49. Pingback: kwtagri
  50. Pingback: knowmorris
  51. Pingback: puenthai
  52. Pingback: cotobobby
  53. Pingback: khodmoni
  54. Pingback: tagderreise
  55. Pingback: surbound
  56. Pingback: putcosales
  57. Pingback: salestraks
  58. Pingback: tsilifeline
  59. Pingback: odgwormald
  60. Pingback: sdadhd
  61. Pingback: iawebservices
  62. Pingback: drfazlani
  63. Pingback: stmnational
  64. Pingback: paradopolis
  65. Pingback: locallers
  66. Pingback: Google
  67. Pingback: braamweg
  68. Pingback: prippinvest
  69. Pingback: xlbutt
  70. Pingback: bitkisayar
  71. Pingback: sdeyelift
  72. Pingback: techieva
  73. Pingback: rydekings
  74. Pingback: carasello
  75. Pingback: nutrytec
  76. Pingback: tuckaghrie
  77. Pingback: spryphotos
  78. Pingback: coleygov
  79. Pingback: thpcstore
  80. Pingback: londonbery
  81. Pingback: statencom
  82. Pingback: fantasyartz
  83. Pingback: zdarusa
  84. Pingback: asisdesigns
  85. Pingback: salmnkhan
  86. Pingback: dmealliance
  87. Pingback: safaristrap
  88. Pingback: respigar
  89. Pingback: fswriting
  90. Pingback: ascarov
  91. Pingback: azoils
  92. Pingback: sisdrog
  93. Pingback: drivingmama
  94. Pingback: bucuburger
  95. Pingback: stlsos
  96. Pingback: ftscrossfit
  97. Pingback: bucumarket
  98. Pingback: skwpartners
  99. Pingback: refbdc
  100. Pingback: stephensng
  101. Pingback: ekytalk
  102. Pingback: gabrichmed
  103. Pingback: webgcd
  104. Pingback: energistech
  105. Pingback: renaytoronto
  106. Pingback: requeil
  107. Pingback: kwlagunabeach
  108. Pingback: annalowther
  109. Pingback: tealsolar
  110. Pingback: buynaoh
  111. Pingback: designinator
  112. Pingback: calmission
  113. Pingback: freedomqdro
  114. Pingback: casahirta
  115. Pingback: aptarismrm
  116. Pingback: tdouglaslaw
  117. Pingback: earcandyllc
  118. Pingback: sinspi
  119. Pingback: debagliano
  120. Pingback: ncgrassfed
  121. Pingback: toptorah
  122. Pingback: cmelements
  123. Pingback: fithelpdesk
  124. Pingback: spagazer
  125. Pingback: stravinci
  126. Pingback: transcapins
  127. Pingback: beernegociant
  128. Pingback: mmmeliacakes
  129. Pingback: motorloaf
  130. Pingback: tosseldorf
  131. Pingback: asecondmind
  132. Pingback: beiritters
  133. Pingback: simairway
  134. Pingback: miltonsport
  135. Pingback: edwinraben
  136. Pingback: nextwavehq
  137. Pingback: bebbrescia
  138. Pingback: limosonoma
  139. Pingback: baltiktur
  140. Pingback: fotodifood
  141. Pingback: antiochfc
  142. Pingback: jbtbrains
  143. Pingback: salankhan
  144. Pingback: etcshowchoir
  145. Pingback: fcpswcs
  146. Pingback: bikeasea
  147. Pingback: dominokirke
  148. Pingback: blogduwem
  149. Pingback: comunidadmh
  150. Pingback: theaudiovirus
  151. Pingback: segurosblog
  152. Pingback: ladagebeheer
  153. Pingback: crcfoods
  154. Pingback: bcapalt
  155. Pingback: bjgruppen
  156. Pingback: wunderboys
  157. Pingback: evestips
  158. Pingback: sdboobjob
  159. Pingback: swiehiantan
  160. Pingback: beursact
  161. Pingback: mfaads
  162. Pingback: tildesheim
  163. Pingback: jfpnyc
  164. Pingback: hotelsamet
  165. Pingback: bakirtesisat
  166. Pingback: etraddes
  167. Pingback: dapasten
  168. Pingback: twittogram
  169. Pingback: laeamerica
  170. Pingback: bksignature
  171. Pingback: fastmlsflyers
  172. Pingback: gestdom
  173. Pingback: sftony
  174. Pingback: karlywegner
  175. Pingback: salmalist
  176. Pingback: tuadventure
  177. Pingback: fibuilders
  178. Pingback: euroweims
  179. Pingback: salmanhan
  180. Pingback: doublesauna
  181. Pingback: czaterianie
  182. Pingback: revealighting
  183. Pingback: thecreagent
  184. Pingback: autodealsva
  185. Pingback: eurorumo
  186. Pingback: candywires
X